Protocols

Disclaimer: The following information is for educational purposes only and is not personalized medical advice. Consult with a qualified healthcare provider before considering any peptide therapy.

The available literature provides limited specific dosing protocols for the combination of BPC-157, TB-500, and GHK-Cu. Most studies examine these peptides individually rather than as a combined therapy. Based on the retrieved research on therapeutic peptides in sports medicine and orthopedics, some general patterns emerge, though evidence remains preliminary.

Individual Peptide Dosing Reported in Literature

BPC-157:

Typical research dosing ranges from 200-500 mcg per injection
Administration often subcutaneous, near the injury site when applicable
Frequency commonly reported as once or twice daily

TB-500 (Thymosin Beta-4):

Research protocols typically use 2-5 mg doses
Usually administered subcutaneously
Dosing frequency ranges from twice weekly to every other day in reported studies

GHK-Cu:

Limited dosing data available in clinical literature
Some studies reference 1-3 mg doses
Subcutaneous administration most commonly reported

Combination Protocol Considerations

The literature indicates that when peptides are used in combination, practitioners may:

Reduce individual peptide doses compared to monotherapy
Stagger injection timing throughout the day
Rotate injection sites to minimize local irritation

Important Limitations

The evidence base for specific dosing protocols remains limited, particularly for combination therapy. Most available data comes from case reports and small observational studies rather than large-scale clinical trials. The retrieved research emphasizes significant variability in dosing approaches across different practitioners and applications.

Critical Note: These peptides are not FDA-approved for most therapeutic uses, and standardized dosing protocols have not been established through rigorous clinical trials. Individual responses may vary significantly, and potential interactions between peptides in combination therapy require further research.

BPC-157 + TB-500 + GHK-Cu

Member access required